Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Oncolytics Biotech Inc. before investing.

In this article, we go over a few key elements for understanding Oncolytics Biotech Inc.’s stock price such as:

• Oncolytics Biotech Inc.’s current stock price and volume
• Why Oncolytics Biotech Inc.’s stock price changed recently
• Upgrades and downgrades for ONCY from analysts
• ONCY’s stock price momentum as measured by its relative strength

About Oncolytics Biotech Inc. (ONCY)

Before we jump into Oncolytics Biotech Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Want to learn more about Oncolytics Biotech Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Oncolytics Biotech Inc..

Oncolytics Biotech Inc.’s Stock Price as of Market Close

As of September 09, 2026, 4:00 PM, CST, Oncolytics Biotech Inc.’s stock price was $0.795.

Oncolytics Biotech Inc. is down 1.24% from its previous closing price of $0.805.

During the last market session, Oncolytics Biotech Inc.’s stock traded between $0.792 and $0.830. Currently, there are approximately 119.74 million shares outstanding for Oncolytics Biotech Inc..

Oncolytics Biotech Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Oncolytics Biotech Inc. Stock Price History

Oncolytics Biotech Inc.’s (ONCY) price is currently down 5.15% so far this month.

During the month of September, Oncolytics Biotech Inc.’s stock price has reached a high of $0.910 and a low of $0.792.

Over the last year, Oncolytics Biotech Inc. has hit prices as high as $1.510 and as low as $0.730. Year to date, Oncolytics Biotech Inc.’s stock is down 9.04%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Oncolytics Biotech Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 09, 2026, there were 0 analysts who downgraded Oncolytics Biotech Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Oncolytics Biotech Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Oncolytics Biotech Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Oncolytics Biotech Inc. (ONCY) by visiting AAII Stock Evaluator.

Relative Price Strength of Oncolytics Biotech Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 09, 2026, Oncolytics Biotech Inc. has a weighted four-quarter relative price strength of -12.90%, which translates to a Momentum Score of 20 and is considered to be Very Weak.

Want to learn more about how Oncolytics Biotech Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Oncolytics Biotech Inc. Stock Price: Bottom Line

As of September 9, 2026, Oncolytics Biotech Inc.’s stock price is $0.795, which is down 1.24% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Oncolytics Biotech Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.